Congresses

Title Yearsort descending
Innovative drug discovery and development strategies for antibacterial therapy: a focus on neglected diseases  2017
Discovery of new therapies for Buruli ulcer treatment 2017
Repurposing clinically approved cephalosporins for tuberculosis therapy 2017
The D2AMR group: Discovery and development of Antimicrobials and Mechanisms of drug Resistance 2017
Development of a high-throughput method for synergistic drug combinations screening 2018
Repurposing beta-lactams for buruli ulcer treatment 2018
REPURPOSING BETA-LACTAMS FOR BURULI ULCER TREATMENT 2018
Preliminary studies to elucidate the mode of action of a new chemical series with antimicrobial activity 2018
Discovery and Development of Antimicrobials and Mechanisms of Drug Resistance 2018
ANTHELMINTIC AVERMECTINS FOR THE TREATMENT OF NON-TUBERCULOUS MYCOBACTERIA INFECTIONS IN CYSTIC FIBROSIS 2018
Anthelmintic avermectins for the treatment of non-tuberculous mycobacteria infections in cystic fibrosis 2018
Caracterización biológica de una nueva serie de compuestos químicos con actividad antimicrobiana 2018
Sesión II: Antimicrobianos (Moderador) 2018
Estudios iniciales para la caracterización del modo de acción molecular de las avermectinas como agentes anti-tuberculosos 2018
Towards the elucidation of rifampicin/betalactam synergistic interactions against M. tuberculosis 2018
Discovery and Development of Antimicrobials and Mechanisms of Drug Resistance 2018
New methodologies to test antibiotic susceptibility against emerging pathogens in cystic fibrosis 2019
Mathematical model of meropenem against Mycobacterium tuberculosis 2019
ESTUDIOS DE ELUCIDACIÓN DEL MODO DE ACCIÓN DE LAS AVERMECTINAS FRENTE A MYCOBACTERIUM 2019
Mode of action elucidation studies of the avermectins against Mycobacteria 2019

Pages